Particulate Form (e.g., Powders, Granules, Beads, Microcapsules, And Pellets) Patents (Class 424/489)
- Containing proteins and derivatives (Class 424/491)
- Containing polysaccharides (e.g., sugars) (Class 424/493)
- Containing natural gums/resins (Class 424/496)
- Containing solid synthetic polymers (Class 424/497)
- Containing waxes, higher fatty acids, higher fatty alcohols, or derivatives thereof (Class 424/498)
-
Patent number: 11993609Abstract: The present disclosure addresses this need by providing crystalline fine particle forms of PRX-3140 potassium salt, methods for preparation and the treatment for Alzheimer's disease (AD) and other dementias affecting the cholinergic and/or serotonergic systems including post-traumatic stress disorder (PTSD). In certain aspects, the present disclosure provides novel methods of preparing the compound of Formula I thereof, or PRX-3140 potassium salts, crystalline fine particle forms of PRX-3140 potassium salt, and compositions comprising them. In certain aspects, the present disclosure provides novel crystalline fine particle form of PRX-3140 potassium salt which may provide advantages including improved bioavailability and stability relative to other crystalline or amorphous forms. In other aspects, the present disclosure provides oral dosage forms of crystalline fine particle form of PRX-3140 potassium salt and excipients with improved stability.Type: GrantFiled: May 10, 2023Date of Patent: May 28, 2024Assignee: Nanopharmaceutics, Inc.Inventors: James David Talton, Mianji Zhang, Lianhao Zhang, Otto Joseph Geoffroy, Daniel Gerard Morgan
-
Patent number: 11980733Abstract: The present invention relates to an apparatus for forming a delivery path for a composition for treatment and an auxiliary assembly for skin treatment including the same, and provides an apparatus for forming a delivery path for a composition for treatment and an auxiliary assembly for skin treatment including the same, the apparatus comprising: a light source; a light irradiating unit for receiving a light from the light source to irradiate the light on a surface of skin; and a control unit for controlling a pulse waveform of a light irradiated through the light irradiating unit so as to form a plurality of pores, which form a path through which a composition applied on the surface of the skin is transferred inside, on the surface of the skin after irradiating the light.Type: GrantFiled: January 8, 2020Date of Patent: May 14, 2024Assignee: Lutronic CorporationInventors: Tae Ho Ha, Bon Cheol Goo
-
Patent number: 11918684Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.Type: GrantFiled: March 12, 2018Date of Patent: March 5, 2024Assignee: LIQMEDS WORLDWIDE LIMITEDInventors: Sandip Mehta, Manish Umrethia, Henil Patel, Jayanta Kumar Mandal
-
Patent number: 11921123Abstract: A quantitative detection method of rare earth doped calcium phosphate fluorescent nanoparticles (RE-nCaP) in organisms includes establishing a fluorescent intensity-concentration standard curve of rare earth ions, preparing samples to be tested and the blank control group into homogenate, performing centrifuging and testing the fluorescent intensity of supernatants, calculating the fluorescent intensity values per unit mass or volume of the samples and the blank control group, and performing significant difference analysis; if P is greater than or equal to 0.05, determining that the RE-nCaP content in the samples is 0, and if P is smaller than 0.05, testing the tissue extraction rate of RE-nCaP; and comprehensively considering the tissue extraction rate, the homogenate volume, the fluorescent intensity value per until mass or volume, the homogenate dilution ratio, and the doping amount to obtain the accurate content of the RE-nCaP in biological tissue samples.Type: GrantFiled: March 18, 2019Date of Patent: March 5, 2024Assignee: WUHAN UNIVERSITY OF TECHNOLOGYInventors: Yingchao Han, Qingguo Xing, Xinyu Wang
-
Patent number: 11921110Abstract: A method for controlled production of an array of planar microparticles with the multiplexing of molecules on the surface thereof, intended to function as molecular sensors and/or actuators and a matrix (array) of microparticles, the surface thereof being printed with all of the molecular components required to provide the surface with functionality. Different molecular elements are multiplexed on the surface of each particle while they are supported on a substrate by means of a structural foot engraved below the particle. These microparticles can be released mechanically from the support on which they are produced using a controlled mechanical rupture method which is not chemically aggressive and therefore does not affect the molecules previously printed on the surface. The array and the particles contained therein offer great versatility in both chemical and/or biological applications.Type: GrantFiled: December 20, 2022Date of Patent: March 5, 2024Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)Inventors: Jaume Esteve Tintó, José Antonio Plaza Plaza, Marta Duch Llobera, Núria Torras Andrés, María Luisa Pérez García, Juan Pablo Agusil Antonoff
-
Patent number: 11883511Abstract: Disclosed are oral care compositions comprising a thickening silica and a fluoride ion source, wherein fluoride is absorbed on the thickening silica and wherein the pH of the composition is below 5.5, as well as to methods of using these compositions. The thickening silica may have a particle size distribution (D95) less than or equal to 7 ?m and a BET surface area of greater than or equal to 150 m2/g.Type: GrantFiled: December 3, 2020Date of Patent: January 30, 2024Assignee: GABA International Holding GmbHInventors: Alan Ceresa, Michael Neumann, Madeleine Manns, Nathalie Coq-Bernard, Andre Brunella, Marian Holerca, Thomas Schollbach
-
Patent number: 11879138Abstract: The present application provides a method for preparing mesenchymal stem cell-derived exosomes, the method including: obtaining a cell sample from mesenchymal stem cells and sub-culturing the cell sample, culturing the sub-cultured cells in a substrate medium containing a protein synthesis inhibitory enzyme, and then obtaining a cell culture solution, and isolating exosomes from the cell culture solution, and a cell culture solution produced therefrom. The method for preparing exosomes of the present application has an advantage in that high purity and high concentration exosomes can be isolated.Type: GrantFiled: June 29, 2020Date of Patent: January 23, 2024Assignee: CK-EXOGENE CO., LTD.Inventors: Jae Young Kim, Yong Joon Chwae
-
Patent number: 11872311Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.Type: GrantFiled: February 25, 2020Date of Patent: January 16, 2024Assignee: The University of North Carolina at Chapel HillInventors: Wenbin Lin, Demin Liu, Joseph Della Rocca, Stephanie Kramer, Christopher Y. Poon
-
Patent number: 11844874Abstract: The present application relates to a lyophilized scaffold composition having at least one polysaccharide wherein said scaffold is substantially solid and capable of being formed into a desired shape; wherein the at least one polysaccharide has a protonation level resulting in controlled rehydration of said scaffold, such that when said scaffold is contacted with at least one of a neutral aqueous solution, blood, blood derived fluid and combinations thereof, said scaffold forms a microparticle dispersion and stimulates tissue remodeling and anabolic wound repair, a process for preparing a lyophilized scaffold composition and the use of a lyophilized scaffold composition for wound repair in a mammal.Type: GrantFiled: February 20, 2015Date of Patent: December 19, 2023Assignee: ORTHO REGENERATIVE TECHNOLOGIES INC.Inventors: Caroline Hoemann, Daniel Veilleux, Michael D. Buschmann
-
Patent number: 11839689Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.Type: GrantFiled: November 11, 2022Date of Patent: December 12, 2023Assignees: Astellas Pharma Inc., Medivation Prostate Therapeutics LLCInventors: Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
-
Patent number: 11819055Abstract: The present disclosure relates to aerosol delivery devices and related methods of delivering aerosol to a user. The aerosol delivery devices may include a housing providing multiple aerosol pathways having a mouth-end opening through which aerosol can be inhaled by a user, the housing defining a first aerosol delivery pathway in fluid communication with the mouth-end opening and a second aerosol delivery pathway separate from the first aerosol delivery pathway and in fluid communication with the mouth-end opening. An atomizer including a heating element or piezoelectric element and a liquid transport element in fluid communication with an aerosol precursor composition is provided in fluid communication with the first aerosol delivery pathway. A flavorant-infused material is positioned within the second aerosol delivery pathway and adapted to produce a second aerosol upon contact between the flavorant-infused material and flowing air.Type: GrantFiled: August 28, 2020Date of Patent: November 21, 2023Assignee: RAI Strategic Holdings, Inc.Inventors: Sawyer Hubbard, Eric Taylor Hunt, Karen V. Taluskie, Stephen Benson Sears, Donna Walker Duggins, Michael F. Davis
-
Patent number: 11819511Abstract: Described herein is a composition based on N-palmitoyl-ethanolamide and Rutin in co-micronized form. In particular, a composition includes a mixture of palmitoyl-ethanolamide (PEA) and Rutin in co-micronized form in which the PEA/Rutin ratio is between 10:1 and 1:1. Pharmaceutical formulations for the treatment of humans and animals are also described. The composition is useable for the treatment of diseases of arteries and arterioles.Type: GrantFiled: August 25, 2020Date of Patent: November 21, 2023Assignee: EPITECH GROUP S.P.A.Inventors: Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo, Salvatore Cuzzocrea, Vito Safina
-
Patent number: 11806330Abstract: Described herein is an active ingredient encapsulated into poly (alkyl cyanoacrylate) nanoparticles and their use in anti-cancer treatments by intraperitoneal administration.Type: GrantFiled: March 27, 2019Date of Patent: November 7, 2023Assignees: SINTEF TTO AS, OSLO UNIVERSITETSSYKEHUS HFInventors: Yrr Morch, Einar Sulheim, Kjersti Flatmark, Karianne Giller Fleten, Per Stenstad, Heidi Johnsen, Ruth Schmid
-
Patent number: 11793222Abstract: Provided herein is a process for increasing the dissolution rate of a sparingly water soluble flavor or taste modifying compound in water comprising: a. mixing the compound and a highly water soluble second compound in a water based solution to form a solution or dispersion of the compound; and b. drying the solution or dispersion to form a solution or solid dispersion of the compound wherein the compound has an increased dissolution rate in water as compared to the compound when dissolved in water alone.Type: GrantFiled: February 1, 2017Date of Patent: October 24, 2023Assignee: Firmenich SAInventors: Pascal Beaussoubre, Wolfgang Fieber, Howard Munt
-
Patent number: 11786463Abstract: The invention provides emulsion compositions comprising at least one cannabinoid compound, and methods for making the same. The emulsion compositions are stable, well tolerated and are capable of delivering therapeutically effective amounts of cannabiniods to target sites, including sites on the surface of and/or within an eye. Also provided are methods of using the compositions to provide ocular neuroprotection and/or to treat ophthalmic conditions such as glaucoma.Type: GrantFiled: August 10, 2018Date of Patent: October 17, 2023Assignee: Rhodes TechnologiesInventors: Ping Chang, Zhenze Hu, Yuanyuan Tao
-
Patent number: 11786549Abstract: The present invention relates to an anti-inflammatory composition comprising a graphene nano-structure as an active ingredient. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease, and a cosmetic composition or feed composition for preventing or improving an inflammatory disease, which include the anti-inflammatory composition, and a method of treating an inflammatory disease, including administering the composition to a subject in need thereof.Type: GrantFiled: November 23, 2018Date of Patent: October 17, 2023Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, BIOGRAPHENE INC.Inventors: Kyung-Sun Kang, Byung-Chul Lee, Jin Young Lee, Jong Bo Park
-
Patent number: 11759529Abstract: A complexation process between a cyclodextrin and active pharmaceutical ingredients is disclosed, and comprises a process for preparing a complex of at least one cyclodextrin and at least one active pharmaceutical ingredient comprising the steps of a. Preparing a first solution (solution A) comprising at least one cyclodextrin and at least one solvent; b. Preparing a second solution (solution B) comprising at least one dissolved, partially dissolved or suspended API; c. Mixing said solution A and solution B by means of a microfludization system to produce a solution and/or suspension of at least one of said complex; d. Isolating said solution and/or suspension and/or optionally drying it; and e. Optionally collecting a powdered form of the complex. The described process has high throughput with higher yields of complexation in less time than prior art methods.Type: GrantFiled: January 27, 2017Date of Patent: September 19, 2023Assignee: Hovione Scientia LimitedInventors: Hugo Lisboa, Márcio Temtem, João Vincente, Filipa Santos
-
Patent number: 11730758Abstract: The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets.Type: GrantFiled: May 18, 2020Date of Patent: August 22, 2023Assignee: The General Hospital CorporationInventors: Dilip Paithankar, Richard Dean Blomgren, Richard Rox Anderson, William A. Farinelli, Apostolos G. Doukas
-
Patent number: 11730749Abstract: Various embodiments of a gut microbiome modulating composition comprises a blend of a polyphenol and an oligosaccharide. Various embodiments of the polyphenol may comprise at least approximately 5% by weight chlorogenic acid. Various embodiments of the oligosaccharides may be standardized to a degree of polymerization of at least three to reduce digestibility. Administration of an effective amount of the gut microbiome modulating composition to a person or animal may stimulate the growth of at least one of Akkermansia muciniphila, Lactobacillus, and Bifidobacterium bacteria in the colon, which may reduce permeability of the colon, increases short chain fatty acid production in the colon, and/or modulate causes immunomodulation of human colon cells. The gut microbiome modulating composition may provide protective effects against obesity-related chronic diseases.Type: GrantFiled: May 7, 2018Date of Patent: August 22, 2023Assignee: Plexus Worldwide, LLCInventors: Stephen Roman, Tianan Jiang, Marco Rebaza
-
Patent number: 11713437Abstract: Slurries that include benefit agent containing delivery particles, compositions that include such particles, and processes for making and using the particles and compositions.Type: GrantFiled: September 10, 2019Date of Patent: August 1, 2023Assignee: The Procter & Gamble CompanyInventors: Johan Smets, Corey James Kenneally, Ariel Lebron, Pascale Claire Annick Vansteenwinckel, Robert Stanley Bobnock, Peggy Dorothy Sands, Todd Arlin Schwantes, Chad Alexander Hladilek
-
Patent number: 11713418Abstract: A quantum dot including zinc, tellurium, selenium, and sulfur, wherein the quantum dot comprises a core and a shell disposed on the core, and wherein the quantum dot is a cadmium-free red light-emitting quantum dot and has an emission peak wavelength of greater than or equal to about 600 nanometers (nm), and efficiency of greater than or equal to about 50%.Type: GrantFiled: December 22, 2021Date of Patent: August 1, 2023Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Yuho Won, Hwea Yoon Kim, Jeong Hee Lee, Eun Joo Jang, Hyo Sook Jang
-
Patent number: 11708546Abstract: Benefit agent containing delivery particles that can be supplied as slurries, compositions comprising such particles, and processes for making and using such particles and compositions.Type: GrantFiled: September 10, 2019Date of Patent: July 25, 2023Assignee: The Procter & Gamble CompanyInventors: Johan Smets, Corey James Kenneally, Ariel Lebron, Pascale Claire Annick Vansteenwinckel, Robert Stanley Bobnock, Peggy Dorothy Sands, Todd Arlin Schwantes, Chad Alexander Hladilek
-
Patent number: 11672763Abstract: The present invention relates to solid dispersions including, but not limited to, co-processed carbohydrates with different solubilities and concentrations, which have a microcrystalline plate structure. The solid dispersions, excipient systems and formulations of the present invention are highly compactable and durable and when compressed into solid dosage forms demonstrate uniform densification, low friability at low pressures, and and/or relatively constant low disintegration times at various hardnesses. The solid dosage forms of the present invention demonstrate superior organoleptics, disintegration, and/or robustness.Type: GrantFiled: May 25, 2016Date of Patent: June 13, 2023Assignee: SPI Pharma, Inc.Inventors: John Tillotson, Cecil Propst
-
Patent number: 11655301Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.Type: GrantFiled: April 13, 2020Date of Patent: May 23, 2023Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Svetomir N. Markovic, Wendy K. Nevala
-
Patent number: 11648261Abstract: A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors, the patient having at least one of a respiratory tract inflammatory disease, a central nervous system inflammatory disease, and vasculitis. The one or more antiviral medications preventing an attachment of viruses to cell walls, blocking a penetration of the viruses into cells, and/or inhibiting virus replication by damaging nucleic acids of the viruses. The one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient.Type: GrantFiled: February 20, 2021Date of Patent: May 16, 2023Inventor: Gholam A. Peyman
-
Patent number: 11642320Abstract: The present invention relates to anti-inflammatory drug formulation. Especially, this invention relates to corticosteroid prodrug nanoparticle. In a first aspect, this invention relates to a nanoparticle comprising a therapeutic agent and a surface coating material. The invention also relates to a process of manufacturing at least one nanoparticle of invention. The invention also relates to pharmaceutical composition and pharmaceutical kits.Type: GrantFiled: September 20, 2017Date of Patent: May 9, 2023Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SACLAYInventors: Elias Fattal, Nicolas Tsapis, Mathilde Lorscheider, Romain Canioni, Franceline Reynaud
-
Patent number: 11633409Abstract: The present invention provides a solid preparation comprising, based on 100 parts by weight of the solid preparation, a self-emulsifying composition comprising 0.1 to 0.5 parts by weight of dutasteride, 6 to 110 parts by weight of oil and 6 to 110 parts by weight of a surfactant, and 5 to 185 parts by weight of a coating excipient having pores accommodating the self-emulsifying composition formed in a surface thereof, and a method of manufacturing the solid preparation.Type: GrantFiled: August 30, 2018Date of Patent: April 25, 2023Assignee: JW PHARMACEUTICAL CORPORATIONInventors: Suk Lee, Min-Uk Cha, Won-Kyu Yang, Min-Seok Choi
-
Patent number: 11633356Abstract: Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.Type: GrantFiled: August 3, 2020Date of Patent: April 25, 2023Assignee: DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S.C.A.R.L.Inventors: Anna Rita Blanco, Maria Luisa Bondi', Gennara Cavallaro, Grazia Maria Letizia Consoli, Emanuela Fabiola Craparo, Gaetano Giammona, Mariano Licciardi, Giovanna Pitarresi, Guiseppe Granata, Patrizia Saladino, Clara La Marca, Irene Ceidda, Salvatore Papasergi, Patrizia Guarneri, Salvatore Cuzzocrea, Emanuela Esposito, Santa Viola
-
Patent number: 11612662Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of pemetrexed-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the pemetrexed-based compound is achieved.Type: GrantFiled: June 25, 2020Date of Patent: March 28, 2023Assignee: Nektar TherapeuticsInventors: Lin Cheng, Jennifer Riggs-Sauthier
-
Patent number: 11607391Abstract: Provided is a microsphere comprising a bead coated with a first calcium-containing mineral. Also provided is a method of producing a microsphere. Additionally, a method of administering a compound to a vertebrate is provided.Type: GrantFiled: September 25, 2009Date of Patent: March 21, 2023Assignee: TRS HOLDINGS LLCInventors: William L. Murphy, Leenaporn Jongpaiboonkit
-
Patent number: 11602548Abstract: A fibrous birth tissue composition fabricated from placental tissue is provided. Methods of processing a mammal's placental tissue to form a fibrous birth tissue composition are provided. Regenerative methods are also provided.Type: GrantFiled: February 25, 2019Date of Patent: March 14, 2023Assignee: CONVATEC, INCInventors: Kurt Klitzke, Jon G. Hargis
-
Patent number: 11597910Abstract: Medical instrument includes a substrate, in which cells are in contact with or held on a surface of the substrate, and at least the surface of the substrate which holds the cells is formed of a fluorine-containing cyclic olefin polymer which contains a repeating structure unit represented by Formula (1), wherein in Formula (1), at least one of R1 to R4 is fluorine, an alkyl with 1 to 10 carbon atoms which contains fluorine, an alkoxy with 1 to 10 carbon atoms which contains fluorine, or an alkoxyalkyl with 2 to 10 carbon atoms which contains fluorine, R1 to R4 are selected from hydrogen and certain non-fluorinated groups when R1 to R4 do not contain fluorine, R1 to R4 may be the same as or different from each other, and R1 to R4 may be bonded to each other to form a cyclic structure.Type: GrantFiled: August 10, 2015Date of Patent: March 7, 2023Assignee: MITSUI CHEMICALS, INC.Inventors: Tadahiro Sunaga, Takashi Oda, Hiroshi Miyasako, Takeshi Osaka
-
Patent number: 11583501Abstract: This patent includes a method for utilizing imaging biomarkers to improve pharmacologic dosing strategies. Specifically, biomarker specific CT and MM examination protocols are disclosed. Dose adjustments based on imaging biomarkers are discussed. Longitudinal analysis of imaging biomarkers is disclosed assess effectiveness of pharmacotherapy and dosing strategies thereof. Finally, manufacturing of a combination pill with day-to-day variations of drug quantities is disclosed.Type: GrantFiled: May 23, 2021Date of Patent: February 21, 2023Inventors: Robert Edwin Douglas, David Byron Douglas, Kathleen Mary Douglas
-
Patent number: 11564889Abstract: Provided are stem cell biomimetic microparticles comprised of at least one stem cell-derived paracrine polypeptide or growth factor embedded in a polymer core particle that further comprises an outer layer of at least one fragment of a cell membrane of a stem cell disposed on the core particle. The polymer core may be constituted of any biocompatible and biodegradable polymer or copolymer, or a combination thereof that allows the embedding of the paracrine factors and their prolonged release from the core. The core and hence the microparticles can be biodegradable, allowing eventual elimination from the recipient animal or human subject. The core particles are sized to allow both transport through blood vessels and extravasation from the blood vessels into the surrounding tissues. The core particle may further include at least one polypeptide or peptide growth factor to induce the generation and proliferation of a population of stem cells.Type: GrantFiled: September 28, 2017Date of Patent: January 31, 2023Assignee: North Carolina State UniversityInventors: Ke Cheng, Junnan Tang
-
Patent number: 11559488Abstract: This invention relates to high drug load compositions of medium chain triglycerides (MCT), and to methods for treatment with such compositions at amounts effective to elevate ketone body concentrations so as to treat conditions associated with reduced neuronal metabolism, for example Alzheimer's disease.Type: GrantFiled: March 15, 2018Date of Patent: January 24, 2023Assignee: Cerecin Inc.Inventors: Aaron M. Badenoch, Taryn Boivin, Devon B. DuBose, Samuel T. Henderson, Christi Lynn Hostetler, David K. Lyon, Craig A. Sather, Matthew J. Shaffer
-
Patent number: 11554178Abstract: Disclosed herein, inter alia, are compositions and methods of modulating macrophage activity. Provided is a method of treating a disease (e.g., a macrophage-associated disease, autoimmune disease, inflammatory disease, or a cancer of an organ in the intraperitoneal cavity), the method including intraperitoneally administering to a subject in need thereof a therapeutically effective amount of a nanoparticle composition or pharmaceutical composition. Provided is a silica nanoparticle non-covalently bound to a plurality of nucleic acids, wherein the silica nanoparticle has a net positive charge in the absence of the plurality of nucleic acids. Provided is a pharmaceutical composition including a nanoparticle composition as described herein, and a pharmaceutically acceptable excipient.Type: GrantFiled: June 29, 2018Date of Patent: January 17, 2023Assignee: CITY OF HOPEInventors: Jacob Berlin, Tom Haber, Yvonne Cornejo
-
Patent number: 11541151Abstract: The present disclosure provides a coacervate composition containing a protein drug, gelatin A, sodium alginate and an acid and a wound-healing agent including the same. The coacervate composition according to the present disclosure can be useful as a wound-healing material delivery system for effectively delivering a protein drug, particularly epidermal growth factor, to a wound site in the wound-healing field.Type: GrantFiled: March 19, 2020Date of Patent: January 3, 2023Assignee: Cha University Industry-Academic Cooperation FoundationInventors: Aeri Kim, Seong Hee Jeong
-
Patent number: 11541007Abstract: A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.Type: GrantFiled: May 16, 2019Date of Patent: January 3, 2023Assignee: MegaPro Biomedical Co., Ltd.Inventors: Ming-Cheng Wei, Yuan-Hung Hsu, Wen-Yuan Hsieh, Chia-Wen Huang, Chih-Lung Chen, Jhih-Yun Jian, Shian-Jy Wang
-
Patent number: 11534446Abstract: It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25° C. and 0% at 37° C. In addition it is provided a method for preparing the pharmaceutical composition.Type: GrantFiled: May 22, 2017Date of Patent: December 27, 2022Assignee: ASARINA PHARMA ABInventors: Torbjörn Bäckström, Anders Carlsson
-
Patent number: 11529426Abstract: Provided are methods and compositions to target delivery of cells to a tissue lesion, thereby treating the lesion. For example, biotinylated antibodies with affinity to a lesion epitope are administered at the lesion. Reparative cells including avidin and biotin are then administered at the lesion. The reparative cells are targeted to the lesion via avidin-biotin bridges to the antibodies, with additional cells recruited to the lesion via cell-to-cell avidin-biotin bridges. In certain examples, antibody-reparative cell complexes are formed by mixing the biotinylated antibodies with the reparative cells including avidin and biotin. The complexes are then administered at the lesion. In other examples, multivalent antibodies are used to target reparative cells to the lesion, such as by binding an epitope at the lesion and an epitope present on the reparative cell. In other examples, the antibodies are chemically linked to a reparative cell or to a nanosome containing a therapeutic agent.Type: GrantFiled: November 18, 2019Date of Patent: December 20, 2022Inventors: Karen Hasty, John Stuart, Mary Christine Patterson, Hongsik Cho
-
Patent number: 11529333Abstract: The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.Type: GrantFiled: March 15, 2019Date of Patent: December 20, 2022Assignee: AZURITY PHARMACEUTICALS, INC.Inventors: Swati Nagar, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Sandeep Pal
-
Patent number: 11510872Abstract: Provided herein are nanoparticle-lipid composite carriers as theranostic agents, particularly for diagnosis and/or treatment of cancers and related diseases and conditions. In particular embodiments, the carrier composites comprise a lipid core and an outer shell of functionalized nanoparticles (fNPs).Type: GrantFiled: May 24, 2018Date of Patent: November 29, 2022Assignee: Northwestern UniversityInventors: Vinayak P. Dravid, Vikas Nandwana
-
Patent number: 11504422Abstract: The present invention relates to a biodegradable nanocomplex. The biodegradable nanocomplex comprises a first electrically charged substance, a charge-redistribution substance, a second electrically charged substance and a carried substance, for holding the carried substance inside. The first electrically charged substance and the carried substance have the same electrical polarity, and the biodegradable nanocomplex has a nonuniformally and positively charge distribution along a radial direction thereof.Type: GrantFiled: August 22, 2016Date of Patent: November 22, 2022Assignee: NATIONAL CHENG KUNG UNIVERSITYInventors: Yee-Shin Lin, Yu-Hung Chen
-
Patent number: 11497737Abstract: The present invention provides compositions (such as pharmaceutical compositions), and commercial batches of such compositions, comprising nanoparticles comprising albumin and rapamycin. The compositions (such as pharmaceutical compositions) have specific physicochemical characteristics and are particularly suitable for use in treating diseases such as cancer. Also provided are methods of making and methods of using the compositions (such as pharmaceutical compositions).Type: GrantFiled: October 28, 2020Date of Patent: November 15, 2022Assignee: Abraxis BioScience, LLCInventor: Neil P. Desai
-
Patent number: 11484506Abstract: The present disclosure is directed to a method of preparing a pharmaceutical composition comprising tolerizing immune-modulating particles of polymer-encapsulated gliadin.Type: GrantFiled: February 21, 2017Date of Patent: November 1, 2022Assignee: COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.Inventors: Daniel R. Getts, Frank Fokta, Ryan Pearson
-
Patent number: 11472705Abstract: Nitric oxide (NO) generating compositions can include a nitrite component, an acidifying component, and a support material configured to carry one of the nitrite component and the acidifying agent. In some examples, the support material can minimize NO generation prior to addition of an activating amount of a suitable solvent.Type: GrantFiled: March 13, 2019Date of Patent: October 18, 2022Assignee: SaNOtize Research and Development Corp.Inventors: Gilly Regev, Christopher C. Miller
-
Patent number: 11471414Abstract: The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.Type: GrantFiled: February 13, 2020Date of Patent: October 18, 2022Assignee: POLYPID LTD.Inventor: Noam Emanuel
-
Patent number: 11471422Abstract: The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.Type: GrantFiled: September 22, 2015Date of Patent: October 18, 2022Inventor: Manu Chaudhary
-
Patent number: 11464741Abstract: The present disclosure provides compositions having different dissolution profiles. In particular, the compositions are formulated by adjusting the types and/or amounts of excipients and/or surfactants, and the compositions are prepared by spray drying processes.Type: GrantFiled: May 27, 2015Date of Patent: October 11, 2022Assignee: SpecGX LLCInventors: Joseph M. Davis, Robert C. Cuca, Edward J. Beasley
-
Patent number: 11458092Abstract: A composition comprising surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein is disclosed, wherein one or more surfactant is utilized for enhancing loading and increasing encapsulation efficiency of cannabinoid passenger molecules within phospholipid structures. A method is disclosed for making a surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein, wherein one or more surfactant is used for enhancing loading and increasing encapsulation efficiency of passenger molecules in phospholipid structures. A method of using surfactant-enhanced phospholipid vesicles with one or more cannabinoid substance encapsulated therein is disclosed wherein one or more surfactant enhances loading and increases encapsulation efficiency of cannabinoid substances in phospholipid structures.Type: GrantFiled: December 6, 2019Date of Patent: October 4, 2022Assignee: NuVessl, Inc.Inventor: Jeffrey S. Reynolds